EUVIMEDEUVIMED entdecken
Crossref

Integrative Molecular Scaffold Generation of PI3K/mTOR Inhibitors Using DeepSARM and Ligand‐Based Virtual Screening Approaches

Kenichiro Shimokawa iD, Yumi N Imai, Yasuyoshi Arikawa, Jianwei Liu, Yiming Wu, Mitsuyo Kondo, Atsushi Yoshimori iD

ChemMedChem · 14.07.2026 · 21 (13)

DOI: 10.1002/cmdc.70362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 08.07.2026. Verfasst von Kenichiro Shimokawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chordia Therapeutics Inc., Fujisawa, Kanagawa, Japan. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Phosphoinositide-3 Kinase Inhibitors, Protein Kinase Inhibitors, MTOR Inhibitors. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Designing novel core scaffolds for small molecules is an important yet challenging task in medicinal chemistry, particularly during the lead‐generation stage and in situations that require alternative chemotypes and/or chemical novelty. In this study, we applied an artificial intelligence‐based structure generation using the DeepSARM methodology to create novel scaffold series and to augment medicinal chemistry capabilities. Samotolisib, a PI3K/mTOR dual inhibitor featuring a tricyclic scaffold, was selected as a model ligand. Following DeepSARM‐guided structure generation and ligand‐based virtual screening, several candidate compounds with simplified scaffolds were identified. Notably, one top‐ranked virtual hit 6 was selected and further optimized into a simplified tool compound 6A for experimental validation. Subsequent synthesis and in vitro evaluation led to the identification of a validated hit bearing a novel nontricyclic scaffold.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsMTOR InhibitorsLigandsPhosphatidylinositol 3-KinasesHumansStructure-Activity RelationshipMolecular StructurePharmacophoreDrug Evaluation, PreclinicalDose-Response Relationship, DrugMolecular Docking Simulation

Stichwörter der Autor:innen

DeepSARMPI3K/mTOR inhibitorsligand‐based virtual screeningpharmacophore modelscaffold generation

Substanzen

LigandsTOR Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsMTOR InhibitorsMTOR protein, human

Autor:innen und Institutionen

  • Chordia Therapeutics Inc., Fujisawa, Kanagawa, Japan.
  • WuXi AppTec Co. Ltd., Shanghai, P. R. China.
  • Axcelead Drug Discovery Partners Inc., Fujisawa, Kanagawa, Japan.
  • Institute for Theoretical Medicine Inc., Fujisawa, Kanagawa, Japan.

ORCID-Profile: Kenichiro Shimokawa, Atsushi Yoshimori

Zitieren

APA

Shimokawa, K., Imai, Y. N., Arikawa, Y., Liu, J., Wu, Y., Kondo, M., & Yoshimori, A. (2026). Integrative Molecular Scaffold Generation of PI3K/mTOR Inhibitors Using DeepSARM and Ligand‐Based Virtual Screening Approaches. ChemMedChem, 21(13). https://doi.org/10.1002/cmdc.70362

Vancouver

Shimokawa K, Imai YN, Arikawa Y, Liu J, Wu Y, Kondo M, et al. Integrative Molecular Scaffold Generation of PI3K/mTOR Inhibitors Using DeepSARM and Ligand‐Based Virtual Screening Approaches. ChemMedChem. 2026;21(13). doi:10.1002/cmdc.70362

BibTeX
@article{Shimokawa2026,
  author = {Shimokawa, Kenichiro and Imai, Yumi N and Arikawa, Yasuyoshi and Liu, Jianwei and Wu, Yiming and Kondo, Mitsuyo and Yoshimori, Atsushi},
  title = {Integrative Molecular Scaffold Generation of PI3K/mTOR Inhibitors Using DeepSARM and Ligand‐Based Virtual Screening Approaches},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {13},
  doi = {10.1002/cmdc.70362}
}
Kostenlos starten →